AUG 7·SEC EDGARLow
Derynck Mika K sold $9.6M of ELVN
Derynck Mika K sold 158,795 shares of Enliven Therapeutics, Inc. (ELVN) at $60.21 ($9.56M total) on 2026-08-04 under a Rule 10b5-1 trading plan.
StockNASDAQ · US · USDHealthcare · Biotechnology
$ELVN
Enliven Therapeutics, Inc.
Price · $ELVNvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $ELVN in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $645K 4 txs
Collins Helen Louise2× · $293K
10b5-1 share of filings100%
Top stories · $ELVNMore →
AUG 5·SEC EDGAR 8-K
Enliven Therapeutics, Inc. (ELVN): Results of Operations and Financial Condition
Enliven Therapeutics, Inc. (ELVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update Announced positive Phase 1 clinical data for ELVN-001 in CML, demonstrating encouraging ELVN-001 efficacy data and a favorable safety and tolerability profile Reached alignme
JUL 17·rttnews.com
Biotech Stocks At 52-Week Highs- CDNA, IART, AGL, BVS, ELVN
Biotech stocks hit 52-week highs on July 16, 2026 ahead of quarterly reports or a conference. CareDx (CDNA) rose to a 52-week high of $40.38% and reported Q1 revenue of $118M. Integra LifeSciences (IART) reached $20.26, with Q1 revenue $391.9M. Bioventus (BVS) hit $12.53, Q1 revenue $132M. Enliven Therapeutics (ELVN) hit $53.89 after a ~$460M public offering.
ELVN sentiment & insider activity
Recent ELVN coverage spans insider activity, financial news and market movers.
In the last 30 days, ELVN insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($645K). The most active reporter was Collins Helen Louise, CHIEF MEDICAL OFFICER, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving ELVN
This is a routine insider sale disclosure with no new operating or guidance catalyst, but it can still affect near-term sentiment and positioning.
Clinical and regulatory progress (Phase 1 efficacy, Fast Track, FDA alignment on Phase 3 design) plus extended cash runway into 2030.
Capital raise plus clinical timeline can be supportive, but dilution risk may cap upside near-term.
This is a routine insider sale under a 10b5-1 plan, with no new operational or financial catalyst disclosed.
A director’s Rule 10b5-1 sale is typically non-informational, but it adds near-term supply/overhang context after a sharp run-up.
alphai scores every news story that mentions ELVN with an AI model for sentiment and relevance, and aggregates insider trades from Enliven Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $ELVN
Score
Derynck Mika K sold $9.6M of ELVN
Derynck Mika K sold 158,795 shares of Enliven Therapeutics, Inc. (ELVN) at $60.21 ($9.56M total) on 2026-08-04 under a Rule 10b5-1 trading plan.
1 min readEnliven Therapeutics, Inc. (ELVN): Results of Operations and Financial Condition
Enliven Therapeutics, Inc. (ELVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update Announced positive Phase 1 clinical data for ELVN-001 in CML, demonstrating encouraging ELVN-001 efficacy data and a favorable safety and tolerability profile Reached alignme
6 min readBiotech Stocks At 52-Week Highs- CDNA, IART, AGL, BVS, ELVN
Biotech stocks hit 52-week highs on July 16, 2026 ahead of quarterly reports or a conference. CareDx (CDNA) rose to a 52-week high of $40.38% and reported Q1 revenue of $118M. Integra LifeSciences (IART) reached $20.26, with Q1 revenue $391.9M. Bioventus (BVS) hit $12.53, Q1 revenue $132M. Enliven Therapeutics (ELVN) hit $53.89 after a ~$460M public offering.
5 min readKunkel Lori Anne sold $505K of ELVN
Kunkel Lori Anne sold 10,000 shares of Enliven Therapeutics, Inc. (ELVN) at an average of $50.49 ($49.98–$50.84, $0.50M total) across 2 trades on 2026-07-06 under a Rule 10b5-1 trading plan.
2 min read
What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%
Enliven Therapeutics director Lori Anne Kunkel sold 10,000 shares for about $345,000 on June 5, 2026, per an SEC Form 4. The weighted average sale price was $34.54; she reduced her direct holdings by 16% to 51,884 shares. The sale followed a Rule 10b5-1 plan adopted March 6, 2026. Shares had risen 62.4% over the prior year.
4 min read
What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally
On June 22, 2026, Orbimed Advisors, a 10% owner of Enliven Therapeutics (ELVN), disclosed an indirect sale of 860,123 shares for about $39.0 million, according to an SEC Form 4. The shares were sold at a weighted average price of $45.36. The sale was 11.6% of Orbimed’s prior indirect holdings; remaining shares are held via OrbiMed funds.
4 min readORBIMED ADVISORS LLC sold $39.0M of ELVN (indirect holdings)
ORBIMED ADVISORS LLC sold 860,123 indirectly-held shares of Enliven Therapeutics, Inc. (ELVN) at an average of $45.36 ($45.00–$45.38, $39.01M total) across 4 trades on 2026-06-22.
2 min read
Enliven Therapeutics moves HQ from Boulder to California – BizWest
Enliven Therapeutics (Nasdaq: ELVN) moved its corporate headquarters from Boulder, Colorado to Burlingame, California, according to SEC prospectus filings and a company spokesperson. The firm says it keeps operations in Boulder. In June it reported $452.4 million in cash and expects runway into H1 2029, with ELVN-001 CML trial phase set for late 2026.
3 min readORBIMED ADVISORS LLC sold $12.7M of ELVN (indirect holdings)
ORBIMED ADVISORS LLC sold 281,408 indirectly-held shares of Enliven Therapeutics, Inc. (ELVN) at $45.02 ($12.67M total) across 2 trades on 2026-06-15.
1 min readEnliven Therapeutics Shares Rise 9%
Enliven Therapeutics (ELVN) shares rose 8.92% to $43.96 on Friday after the company priced an upsized public offering expected to raise about $400 million in gross proceeds, according to the article. Enliven sold 8.93 million shares at $37.50 plus pre-funded warrants. Volume was 2.49 million shares versus a 1.20 million average.
2 min read